Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial.

被引：0
|
作者：
Fukasawa, Satoshi
Suzuki, Hiroyoshi
Sato, Fuminori
Hashine, Katsuyoshi
Hasumi, Hisashi
Matsumoto, Hiroaki
Tsuchiya, Tomohiro
Uemura, Hirotsugu
Oya, Mototsugu
Kanayama, Hiroomi
Kawaguchi, Kazushiro
Noguchi, Hidehisa
Enjo, Kentaro
Tran, Namphuong
Todd, Mary Beth
Fizazi, Karim
Matsubara, Nobuaki
机构：
[1] Chiba Canc Ctr Hosp, Chiba, Japan
[2] Toho Univ, Sakura Med Ctr, Sakura, Japan
[3] Oita Univ, Oita, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[5] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa, Japan
[6] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan
[7] Gifu Univ, Grad Sch Med, Gifu, Japan
[8] Kinki Univ, Sch Med, Osaka, Japan
[9] Keio Univ, Sch Med, Tokyo, Japan
[10] Tokushima Univ, Grad Sch, Tokushima, Japan
[11] Janssen Pharmaceut K K, Tokyo, Japan
[12] Janssen Pharmaceut K K, Chiyoda Ku, Tokyo, Japan
[13] Janssen Res Dev, LLC, Los Angeles, CA USA
[14] Janssen Global Serv, Raritan, NJ USA
[15] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France
[16] Natl Canc Ctr Hosp E, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.286
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Posadas, Edwin M.
    Chit, Kim N.
    de Wit, Ronald
    de Jonge, Maja J. A.
    Attard, Gerhardt
    Friedlander, Terence
    Yu, Margaret
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene
    Gonzalez, Martha
    Trudel, Geralyn C.
    Chauhan, Vijay
    Saad, Fred
    CANCER RESEARCH, 2015, 75
  • [22] Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)
    Woo, H.
    Fizaz, K.
    Sulur, G.
    Tran, N.
    Fein, L.
    Matsubara, N.
    Rodriguez-Antolin, A.
    Alekseev, B.
    Ozguroglu, M.
    Ye, D.
    Feyerabend, S.
    Protheroe, A.
    Li, S.
    Luna, Y.
    Mundle, S.
    Chi, K.
    BJU INTERNATIONAL, 2019, 123 : 27 - 28
  • [23] Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).
    Fizazi, Karim
    Namphuong Tran
    Fein, Luis Enrique
    Matsubara, Nobuaki
    Antolin, Alfredo Rodriguez
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Efficacy and safety of abiraterone acetate (AA) in elderly (75 years) chemo-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Smith, M. R.
    Rathkopf, D.
    Mulders, P.
    Carles, J.
    Van Poppel, H.
    Li, J.
    Kheoh, T.
    Griffin, T.
    Molina, A.
    Ryan, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S708 - S708
  • [25] Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
    Rathkopf, Dana E.
    Smith, Matthew R.
    De Bono, Johann Sebastian
    Logothetis, Christopher
    Shore, Neal
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Fradet, Yves
    Griffin, Thomas W.
    Park, Youn Choi
    Kheoh, Thian San
    Small, Eric Jay
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naive prostate cancer (M0HNPC).
    Hahn, Andrew Warren
    Wang, Xuemei
    Efstathiou, Eleni
    Hwang, Hyunsoo
    Zurita, Amado J.
    Spetsieris, Nicholas
    Boukovala, Myrto A.
    Wang, Jennifer
    Araujo, John C.
    Pilie, Patrick Glen
    Siddiqui, Bilal A.
    Subudhi, Sumit Kumar
    Corn, Paul Gettys
    Aparicio, Ana
    Tu, Shi-Ming
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [27] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [28] IMPACT OF ABIRATERONE ACETATE IN PROSTATE SPECIFIC ANTIGEN TRIAL UPDATE: EFFECT OF ABIRATERONE ACETATE AND LOW DOSE PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN AND RADIOGRAPHIC DISEASE PROGRESSION IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Ryan, Charles
    Crawford, E. David
    Shore, Neal D.
    Beach, Myrtle
    Underwood, Willie
    Londhe, Anil
    Black, Shawn
    McGowan, Tracy
    Kantoff, Philip W.
    JOURNAL OF UROLOGY, 2016, 195 (04): : E680 - E680
  • [29] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    LANCET ONCOLOGY, 2019, 20 (05): : 686 - 700
  • [30] Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).
    Fizazi, Karim
    Chi, Kim N.
    De Bono, Johann Sebastian
    Gomella, Leonard G.
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pehlivanov, Nonko
    Charnas, Robert Louis
    Todd, Mary Beth
    Montgomery, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345